Alseroxylon (Rautensin, Rauwiloid) is a norepinephrine reuptake inhibitor that has been investigated in the treatment of hypertension[1] and angina pectoris and as a sedative in psychoses.[2] It was at one time approved for use in the United States, but has since been discontinued.[3]

Alseroxylon
Reserpine, the major component of alseroxylon
Clinical data
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • None
UNII
ChEMBL
Chemical and physical data
FormulaVaries
 ☒NcheckY (what is this?)  (verify)

Alseroxylon is a purified fat-soluble extract of the root of Rauvolfia serpentina, containing reserpine and other nonadrenolytic amorphous alkaloids.[2]

References

edit
  1. ^ Green RS, Davolos D (May 1956). "A long-term study of the effect of crude Rauwolfia serpentina and of its alseroxylon fraction in patients with hypertension". The American Journal of Medicine. 20 (5): 760–73. doi:10.1016/0002-9343(56)90158-9. PMID 13313574.
  2. ^ a b DrugBank DB00386
  3. ^ Approved Drug Products with Therapeutic Equivalence Evaluations (33rd ed.). 2013. {{cite book}}: |work= ignored (help)